Addex Pharmaceuticals (ADXN.SW) ADX10059 Monotherapy is Effective on GERD Symptoms in Phase IIb Clinical Trial
11/16/2009 11:11:55 AM
More...
|
Addex Pharmaceuticals (ADXN.SW) Completes Enrollment of First Mid-Stage Clinical GERD Trial
9/28/2009 10:49:27 AM
More...
|
Laurent Massuyeau, Head of Business Development At Addex Pharmaceuticals (ADXN.SW) Resigns
9/17/2009 11:42:34 AM
More...
|
Addex Pharmaceuticals (ADXN.SW)' ADX10059 Has Potential For Parkinson's Disease Levodopa Induced Dyskinesia (PD-LID)
9/14/2009 11:22:08 AM
More...
|
Addex Pharmaceuticals (ADXN.SW) Reports First Half 2009 Financial Results
7/28/2009 11:21:54 AM
More...
|
Addex Pharmaceuticals (ADXN.SW) First Half 2009 Financial Results Tuesday, July 28
7/23/2009 11:09:35 AM
More...
|
Addex Pharmaceuticals (ADXN.SW) R&D Day Highlights Broadened Therapeutic Potential of Allosteric Modulation Platform to Include Cytokine Receptors as Well as GPCRs
7/16/2009 10:48:04 AM
More...
|
Addex Pharmaceuticals (ADXN.SW) Achieves Second Milestone in Parkinson's Disease Collaboration With Merck & Co., Inc. (MRK)
7/10/2009 6:38:19 AM
More...
|
Addex Pharmaceuticals (ADXN.SW) to Host R&D Day on July 16
7/6/2009 11:59:18 AM
More...
|
Addex Pharmaceuticals (ADXN.SW) Partner Ortho-McNeil-Janssen Pharmaceuticals, Inc. Starts First-Ever Clinical Trial of an mGluR Positive Allosteric Modulator
6/24/2009 10:28:05 AM
More...
|
|